Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer

Authors: Hui Jiang, Xueying Mao, Xiaoyi Huang, Jing Zhao, Lumei Wang, Jingjing Xu, Hongwei Zhang, Yongjie Lu, Yongwei Yu

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

Prostate cancer is the commonest male malignancy in the Western world, but its morbidity is much lower in China. The principal aim of this study was to evaluate the frequency of TMPRSS2:ERG fusion in Chinese prostate cancer patients using immunohistochemistry and reverse transcription polymerase chain (RT-PCR). In addition, we compared the ERG protein expression with TMPRSS2:ERG fusion gene. The relationship between ERG expression and clinicopathologic features was also examined. Samples from patients who underwent radical prostatectomies in Changhai Hospital (Shanghai, China) were collected and stored in ethically approved tissue banks. One hundred seventy-four prostate cancer tissue samples and 10 normal tissues were marked on standard hematoxylin–eosin (HE) sections, punched out of the paraffin blocks and inserted into a recipient block using tissue arrayer instruments. Immunohistochemistry and RT-PCR were employed to detect TMPRSS2:ERG fusion gene. ERG was highly expressed in the nuclei of endothelial cells of vessels and weak cytoplasmic staining was occasionally observed. ERG positive staining was present in 14.9 % (26/174) of the tumor samples in microarray. All benign prostate samples were found to be negative. RT-PCR results revealed that 11.1 % (15/135) were TMPRSS2:ERG fusion positive. Altogether, there was a good agreement of ERG immunostaining with the presence of TMPRSS2:ERG. However, no correlation was observed between ERG expression and age, Gleason score, stage, surgical margin, and seminal vesicle involvement in Chinese patients. In the present study, we identified a high correlation between ERG expression and ERG TMPRSS2:ERG, with 100 % sensitivity and 88.9 % specificity. The expression level of ERG was unrelated to the age, Gleason score, stage, surgical margin, and seminal vesicle involvement. Therefore, the association between ERG expression and prostate cancer based on Chinese population should be further investigated in the future.
Literature
1.
Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2.
Shan L, Ambroisine L, Clark J, et al. The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(2):117–25.
3.
Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64.
4.
Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer Care. 2005;41(6):834–45.
5.
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of tmprss2 and ets transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.
6.
Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233–45.
7.
Vaarala MH, Porvari KS, Kellokumpu S, et al. Expression of transmembrane serine protease tmprss2 in mouse and human tissues. J Pathol. 2001;193(1):134–40.
8.
Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease tmprss2. Cancer Res. 1999;59(17):4180–4.
9.
Vaarala MH, Porvari K, Kyllonen A, et al. The tmprss2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated tmprss2 form in a case of aggressive disease. Int J Cancer. 2001;94(5):705–10.
10.
Afar DE, Vivanco I, Hubert RS, et al. Catalytic cleavage of the androgen-regulated tmprss2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 2001;61(4):1686–92.
11.
Liu W, Chang B, Sauvageot J, et al. Comprehensive assessment of DNA copy number alterations in human prostate cancers using affymetrix 100k snp mapping array. Genes Chromosomes Cancer. 2006;45(11):1018–32.
12.
Mehra R, Tomlins SA, Yu J, et al. Characterization of tmprss2-ets gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68(10):3584–90.
13.
Perner S, Demichelis F, Beroukhim R, et al. Tmprss2:Erg fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337–41.
14.
Mao X, Yu Y, Boyd LK, et al. Distinct genomic alterations in prostate cancers in chinese and western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010;70(13):5207–12.
15.
Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 2012;22(5):806–21.
16.
Xue L, Mao X, Ren G, et al. Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. Am J Cancer Res. 2012;2(6):736–44.
17.
Xiang H, Ling Z, Sun K, et al. Detection and significance of fusion gene between TMPRSS2 and ETS transcription factor genes in fresh prostatic cancer tissues in Chinese patients. Zhonghua Bing Li Xue Za Zhi. 2011;40(3):187–8.
18.
Wang J, Liu Y, Wang W, et al. Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China. Asian Pac J Cancer Prev. 2012;13(10):4935–8.
19.
Sun Q, Li L, Chen Z, et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J Mol Diagn. 2010;12(5):718–24.
20.
Dong J, Xiao L, Sheng L, et al. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Asian Pac J Cancer Prev. 2014;15(7):3099–103.
21.
Dai M, Chen L, Zheng Y, et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Zhonghua Yi Xue Za Zhi. 2008;88(10):669–73.
22.
Miyagi Y, Sasaki T, Fujinami K, et al. Ets family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mol Pathol. 2010;23(11):1492–8.
23.
Furusato B, van Leenders GJ, Trapman J, et al. Immunohistochemical ets-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int. 2011;61(7):409–14.
24.
Lee K, Chae JY, Kwak C, et al. Tmprss2-erg gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology. 2010;76(5):1268 e7-13.
25.
Epstein JI, Allsbrook Jr WC, et al. The 2005 international society of urological pathology (isup) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.
26.
He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker erg in the workup of prostate biopsies with “atypical glands suspicious for cancer”. Am J Surg Pathol. 2011;35(4):608–14.
27.
van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody epr3864 is specific for erg genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24(8):1128–38.
28.
Ji JH, Oh YL, Hong M, et al. Identification of driving alk fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genet. 2015;11(8):e1005467.
29.
Salzman J, Marinelli RJ, Wang PL, et al. Esrra-c11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol. 2011;9(9):e1001156.
30.
Park K, Dalton JT, Narayanan R, et al. Tmprss2:Erg gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol. 2014;32(3):206–11.
31.
Leyten GH, Hessels D, Jannink SA, et al. Hulsbergen-van de Kaa CA, Schalken JA: prospective multicentre evaluation of pca3 and tmprss2-erg gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65:534–42.
32.
Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG, et al. Erg protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol. 2014;66(3):851–60.
33.
Font-Tello A, Juanpere N, de Muga S, et al. Association of erg and tmprss2-erg with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. Prostate. 2015;75(11):1216–26.
34.
Kim SH, Joung JY, Lee GK, et al. Overexpression of erg and wild-type pten are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancer. PloS one. 2015;10(4):e0122498.
35.
Zhau HE, Li Q, Chung LW. Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian J Androl. 2013;15(6):705–7.
36.
Faisal FA, Sundi D, Tosoian JJ, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016;70(1):14–7.
37.
Qi M, Yang X, Zhang F, et al. Erg rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PloS one. 2014;9(2):e84959.
38.
Rouzier C, Haudebourg J, Carpentier X, et al. Detection of the tmprss2-ets fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet. 2008;183(1):21–7.
39.
Lapointe J, Kim YH, Miller MA, et al. A variant tmprss2 isoform and erg fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 2007;20(4):467–73.
40.
Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of tmprss2 and ets family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20(5):538–44.
41.
FitzGerald LM, Agalliu I, Johnson K, et al. Association of tmprss2-erg gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC cancer. 2008;8:230.
42.
Saramaki OR, Harjula AE, Martikainen PM, et al. Tmprss2:Erg fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008;14(11):3395–400.
Metadata
Title
TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer
Authors
Hui Jiang
Xueying Mao
Xiaoyi Huang
Jing Zhao
Lumei Wang
Jingjing Xu
Hongwei Zhang
Yongjie Lu
Yongwei Yu
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5116-9

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue

Original Article

Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery

Original Article

Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation

Original Article

Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis

Review

Emerging targets for radioprotection and radiosensitization in radiotherapy

Review

Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs—syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin’s lymphoma

Original Article

Overexpression of LncRNA-ROR predicts a poor outcome in gallbladder cancer patients and promotes the tumor cells proliferation, migration, and invasion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits